Categories: Wire Stories

Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S.

SAN DIEGO–(BUSINESS WIRE)–Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S. Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers.




Inocras specializes in cancer profiling using whole genome sequencing (WGS), capturing over 99% of an individual’s genomic makeup. This allows for a broader analysis of mutations and complex variations, allowing for deeper insights into a patient’s condition. IMBdx has developed a comprehensive portfolio of liquid biopsies for the cancer diagnosis and treatment cycle. The company was recently listed on the KOSDAQ in South Korea.

The partnership will focus on Inocras providing IMBdx’s liquid biopsy-based cancer diagnostics in the U.S. market, creating alternatives for patients and their providers when genetic testing from tissue biopsy is not feasible. This joint initiative introduces a new model of patient care, leveraging advanced two technologies in genetic testing – whole genome data and liquid biopsy.

“Our collaboration with IMBdx marks a significant step forward in our mission to transform healthcare for cancer and rare disease patients,” said Jehee Suh, CEO of Inocras. “We think of patients at the core and are trying to create more options for patients and providers. By combining our strengths, we’re not just delivering advanced diagnostic services, we’re contributing to creating a pathway to a more effective cancer care journey.”

About Inocras Inc:

Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics for cancer and rare diseases. The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone. For more information about Inocras and our services, please visit Inocras.com.

About IMBdx:

IMBdx is at the forefront of liquid biopsy technology, developing advanced diagnostic tools that capture and analyze circulating biomarkers to detect and monitor diseases more effectively and non-invasively.

Contacts

Sohee Cho / media@inocras.com

Alex

Recent Posts

Artistic Biomedical Limited Company Garners Two Accolades at the Asia Pacific Enterprise Awards 2024 Taiwan

SINGAPORE - Media OutReach Newswire - 6 November 2024 - Artistic Biomedical Limited Company took…

54 mins ago

Awesome Group Honored With Two Awards at the Asia Pacific Enterprise Awards 2024 Taiwan Chapter

SINGAPORE - Media OutReach Newswire - 6 November 2024 - Leading education & training brand,…

54 mins ago

Asia Responsible Enterprise Awards 2024 China Chapter Shines Light on ESG Champions Setting the Standard for Sustainability in Asia

SHANGHAI, CHINA - Media OutReach Newswire - 6 November 2024 - The Asia Responsible Enterprise…

1 hour ago

China Wantian Holdings was awarded the “2024 Hong Kong International ESG Award”

HONG KONG SAR – Media OutReach Newswire - 6 November 2024 - At the "2024…

3 hours ago

JustMarkets Gala Dinner 2024 — This Year’s Most Splendid and Rewarding Trading Event

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 6 November 2024 - On the 28th…

5 hours ago

St. George’s University Emphasizes Pathology’s Critical Role in Advancing South Korea’s Healthcare Systems on World Pathology Day

SEOUL, SOUTH KOREA - Media OutReach Newswire - 6 November 2024 - On World Pathology…

6 hours ago